ADESSO SE (ADN1.DE) Fundamental Analysis & Valuation

FRA:ADN1 • DE000A0Z23Q5

Current stock price

59.6 EUR
+0.5 (+0.85%)
Last:

This ADN1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. ADN1.DE Profitability Analysis

1.1 Basic Checks

  • ADN1 had positive earnings in the past year.
  • In the past year ADN1 had a positive cash flow from operations.
  • Each year in the past 5 years ADN1 has been profitable.
  • Each year in the past 5 years ADN1 had a positive operating cash flow.
ADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

  • ADN1 has a worse Return On Assets (2.45%) than 60.27% of its industry peers.
  • ADN1 has a Return On Equity (10.90%) which is in line with its industry peers.
  • With a Return On Invested Capital value of 5.23%, ADN1 is not doing good in the industry: 64.38% of the companies in the same industry are doing better.
  • Measured over the past 3 years, the Average Return On Invested Capital for ADN1 is significantly below the industry average of 12.04%.
  • The last Return On Invested Capital (5.23%) for ADN1 is above the 3 year average (3.16%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROIC 5.23%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ADN1.DE Yearly ROA, ROE, ROICADN1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.99%, ADN1 is doing worse than 64.38% of the companies in the same industry.
  • ADN1's Profit Margin has declined in the last couple of years.
  • ADN1 has a worse Operating Margin (2.96%) than 67.12% of its industry peers.
  • ADN1's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 85.30%, ADN1 is in the better half of the industry, outperforming 76.71% of the companies in the same industry.
  • ADN1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
ADN1.DE Yearly Profit, Operating, Gross MarginsADN1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

4

2. ADN1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ADN1 is still creating some value.
  • ADN1 has less shares outstanding than it did 1 year ago.
  • ADN1 has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ADN1 has been reduced compared to a year ago.
ADN1.DE Yearly Shares OutstandingADN1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADN1.DE Yearly Total Debt VS Total AssetsADN1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • ADN1 has an Altman-Z score of 3.45. This indicates that ADN1 is financially healthy and has little risk of bankruptcy at the moment.
  • ADN1 has a Altman-Z score of 3.45. This is in the better half of the industry: ADN1 outperforms 78.08% of its industry peers.
  • ADN1 has a debt to FCF ratio of 7.88. This is a slightly negative value and a sign of low solvency as ADN1 would need 7.88 years to pay back of all of its debts.
  • ADN1's Debt to FCF ratio of 7.88 is on the low side compared to the rest of the industry. ADN1 is outperformed by 67.12% of its industry peers.
  • A Debt/Equity ratio of 1.60 is on the high side and indicates that ADN1 has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.60, ADN1 is doing worse than 76.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Altman-Z 3.45
ROIC/WACC1.02
WACC5.15%
ADN1.DE Yearly LT Debt VS Equity VS FCFADN1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 1.30 indicates that ADN1 should not have too much problems paying its short term obligations.
  • ADN1's Current ratio of 1.30 is in line compared to the rest of the industry. ADN1 outperforms 57.53% of its industry peers.
  • A Quick Ratio of 1.30 indicates that ADN1 should not have too much problems paying its short term obligations.
  • ADN1 has a better Quick ratio (1.30) than 64.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
ADN1.DE Yearly Current Assets VS Current LiabilitesADN1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

8

3. ADN1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 200.98% over the past year.
  • The earnings per share for ADN1 have been decreasing by -15.02% on average. This is quite bad
  • ADN1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.60%.
  • The Revenue has been growing by 23.60% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%

3.2 Future

  • ADN1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.90% yearly.
  • The Revenue is expected to grow by 10.64% on average over the next years. This is quite good.
EPS Next Y79.75%
EPS Next 2Y72.14%
EPS Next 3Y59.17%
EPS Next 5Y40.9%
Revenue Next Year11.29%
Revenue Next 2Y10.88%
Revenue Next 3Y10.64%
Revenue Next 5Y10.64%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADN1.DE Yearly Revenue VS EstimatesADN1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
ADN1.DE Yearly EPS VS EstimatesADN1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10

6

4. ADN1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 18.68, the valuation of ADN1 can be described as rather expensive.
  • ADN1's Price/Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Earnings ratio of 25.60, ADN1 is valued a bit cheaper.
  • With a Price/Forward Earnings ratio of 11.03, the valuation of ADN1 can be described as very reasonable.
  • Based on the Price/Forward Earnings ratio, ADN1 is valued a bit cheaper than 68.49% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of ADN1 to the average of the S&P500 Index (22.84), we can say ADN1 is valued rather cheaply.
Industry RankSector Rank
PE 18.68
Fwd PE 11.03
ADN1.DE Price Earnings VS Forward Price EarningsADN1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADN1 indicates a somewhat cheap valuation: ADN1 is cheaper than 71.23% of the companies listed in the same industry.
  • 72.60% of the companies in the same industry are more expensive than ADN1, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 8.33
EV/EBITDA 5.21
ADN1.DE Per share dataADN1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ADN1's earnings are expected to grow with 59.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y72.14%
EPS Next 3Y59.17%

5

5. ADN1.DE Dividend Analysis

5.1 Amount

  • ADN1 has a Yearly Dividend Yield of 1.38%.
  • The stock price of ADN1 dropped by -31.89% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • ADN1's Dividend Yield is comparable with the industry average which is at 2.90.
  • ADN1's Dividend Yield is slightly below the S&P500 average, which is at 1.88.
Industry RankSector Rank
Dividend Yield 1.38%

5.2 History

  • The dividend of ADN1 is nicely growing with an annual growth rate of 15.65%!
Dividend Growth(5Y)15.65%
Div Incr Years5
Div Non Decr Years6
ADN1.DE Yearly Dividends per shareADN1.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • 31.75% of the earnings are spent on dividend by ADN1. This is a low number and sustainable payout ratio.
  • ADN1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP31.75%
EPS Next 2Y72.14%
EPS Next 3Y59.17%
ADN1.DE Yearly Income VS Free CF VS DividendADN1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADN1.DE Dividend Payout.ADN1.DE Dividend Payout, showing the Payout Ratio.ADN1.DE Dividend Payout.PayoutRetained Earnings

ADN1.DE Fundamentals: All Metrics, Ratios and Statistics

ADESSO SE

FRA:ADN1 (4/2/2026, 7:00:00 PM)

59.6

+0.5 (+0.85%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)11-12
Earnings (Next)03-31
Inst Owners19.64%
Inst Owner ChangeN/A
Ins Owners50.29%
Ins Owner ChangeN/A
Market Cap389.19M
Revenue(TTM)2.10B
Net Income(TTM)20.84M
Analysts83.33
Price Target128.52 (115.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.38%
Yearly Dividend0.94
Dividend Growth(5Y)15.65%
DP31.75%
Div Incr Years5
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.43%
PT rev (3m)1.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.07%
EPS NY rev (3m)-2.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.68%
Valuation
Industry RankSector Rank
PE 18.68
Fwd PE 11.03
P/S 0.19
P/FCF 8.33
P/OCF 5.01
P/B 2.04
P/tB 7.69
EV/EBITDA 5.21
EPS(TTM)3.19
EY5.35%
EPS(NY)5.4
Fwd EY9.07%
FCF(TTM)7.16
FCFY12.01%
OCF(TTM)11.9
OCFY19.96%
SpS322.11
BVpS29.27
TBVpS7.75
PEG (NY)0.23
PEG (5Y)N/A
Graham Number45.84
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROCE 11.91%
ROIC 5.23%
ROICexc 5.78%
ROICexgc 8.22%
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
FCFM 2.22%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ROICexc(3y)4.06%
ROICexc(5y)6.01%
ROICexgc(3y)6.65%
ROICexgc(5y)10.11%
ROCE(3y)7.2%
ROCE(5y)10.26%
ROICexgc growth 3Y-20.34%
ROICexgc growth 5Y-12.01%
ROICexc growth 3Y-21.84%
ROICexc growth 5Y-11.01%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
F-Score7
Asset Turnover2.47
Health
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Debt/EBITDA 2.26
Cap/Depr 42.37%
Cap/Sales 1.47%
Interest Coverage 5.03
Cash Conversion 57.42%
Profit Quality 224.33%
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z 3.45
F-Score7
WACC5.15%
ROIC/WACC1.02
Cap/Depr(3y)52.06%
Cap/Depr(5y)49.68%
Cap/Sales(3y)2.64%
Cap/Sales(5y)2.54%
Profit Quality(3y)790.41%
Profit Quality(5y)538.39%
High Growth Momentum
Growth
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
EPS Next Y79.75%
EPS Next 2Y72.14%
EPS Next 3Y59.17%
EPS Next 5Y40.9%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%
Revenue Next Year11.29%
Revenue Next 2Y10.88%
Revenue Next 3Y10.64%
Revenue Next 5Y10.64%
EBIT growth 1Y38.36%
EBIT growth 3Y-13.12%
EBIT growth 5Y5.01%
EBIT Next Year308.27%
EBIT Next 3Y79.27%
EBIT Next 5Y45.14%
FCF growth 1Y300.77%
FCF growth 3Y40.19%
FCF growth 5Y49.54%
OCF growth 1Y1010.67%
OCF growth 3Y32.14%
OCF growth 5Y37.69%

ADESSO SE / ADN1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ADN1.DE.


Can you provide the valuation status for ADESSO SE?

ChartMill assigns a valuation rating of 6 / 10 to ADESSO SE (ADN1.DE). This can be considered as Fairly Valued.


How profitable is ADESSO SE (ADN1.DE) stock?

ADESSO SE (ADN1.DE) has a profitability rating of 4 / 10.


What is the financial health of ADESSO SE (ADN1.DE) stock?

The financial health rating of ADESSO SE (ADN1.DE) is 4 / 10.


Can you provide the dividend sustainability for ADN1 stock?

The dividend rating of ADESSO SE (ADN1.DE) is 5 / 10 and the dividend payout ratio is 31.75%.